Company: ARVN
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001655759-25-000075
Chunk: 56

Company: ARVINAS, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 56
---
 |     |               | 93,879 |     |      | 63,452 |
| Angela Cacace, Ph.D. (5)        |     |               | 24,632 |     |      | 15,995 |

(1) Reflects annual equity grants made in February 2024.

(2) Reflects grants made on June 24, 2024 a s an inducement material to entering into employment with us and in accordance with Nasdaq Listing Rule 5635(c)(4), and not pursuant to our 2018 Plan. The inducement Options vest over four years with 25% of the shares underlying the awards vesting on June 24, 2025, and the remainder of the shares vesting in equal monthly installments. The inducement RSUs vest over four years in equal annual installments. The exercise price for these inducement Options granted was $24.97 which was equal to the closing price of our common stock on the Nasdaq Global Select Market on the date of grant.

(3) Reflects grants made on May 21, 2024, in connection with Dr. Teel’s appointment as our Chief Business Officer, pursuant to our 2018 Plan. The Options and RSUs vest over two years with 50% of the shares underlying the awards vesting on April 21, 2025, and the remainder of the shares vesting on April 21, 2026. The exercise price for these Options granted was $34.65 which was equal to the closing price of our common stock on the Nasdaq Global Select Market on the date of grant.

(4) Reflects grants made on March 18, 2024 a s an inducement material to entering into employment with us and in accordance with Nasdaq Listing Rule 5635(c)(4), and not pursuant to our 2018 Plan. The inducement Options vest over four years with 25% of the shares underlying the awards vested on March 18, 2025, and the remainder of the shares vesting in equal monthly installments. The inducement RSUs vest over four years in equal annual installments. The exercise price for these inducement Options granted was $42.60 which was equal to the closing price of our common stock on the Nasdaq Global Select Market on the date of grant.

(5) Reflects grants made on June 17, 2024, in connection with Dr.